The arrival of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable interest within the healthcare community. This innovative dual GIP and GLP-1 agonist medication seems to provide significant improvements in weight loss compared to previous therapies. Initial clinical trials have demonstrated marked declines in weight , conceivably m